The LiquiDx consortium gathered for its third annual coordination meeting on 31st October 2024 at Leitat’s facilities at the Parc Cientific de Barcelona. The meeting reviewed the project’s progress toward developing a cutting-edge RNA-based blood diagnostic tool to enable early detection of five types of cancer: lung, colon, breast, prostate, and pancreas.
Key highlights from the meeting included:
- Sample Collection and Processing: The Biobank of the Andalusian Public Health System (BBSSPA) has delivered 1,029 high-quality plasma samples to Flomics.
- Enhanced Lab Capacity: Flomics, with support from Leitat, significantly expanded its wet-lab capabilities, with 756 samples processed to libraries (of which 564 sequenced) in the last six months alone.
- Advanced Bioinformatics Pipeline: The bioinformatics team has put a robust, scalable, and reproducible analysis pipeline into production. They have performed 196 analysis runs (including debugging) and processed raw data exceeding 3.09 TiB across 600 samples.
These developments underscore the consortium’s commitment to revolutionizing early cancer detection and accelerating the diagnostic project’s success.
It is important to point out that this line of work forms part of the LiquiDx project, associated with the action with action file number CPP2021-008897, which is financed by MCIN/AEI/10.13039/501100011033 and by the European Union “NextGenerationEU/PRTR”, through the 2021 call for public-private collaboration projects of the Agencia Estatal de Investigación.
